Macro & Micro-Test Comprehensive Dengue Testing Solutions -From Rapid Screening to Precision Diagnosis and Outbreak Surveillance

Macro & Micro-Test Comprehensive Dengue Testing Solutions

-From Rapid Screening to Precision Diagnosis and Outbreak Surveillance

Dengue is no longer a localized tropical disease. Its geographic range and public health impact continue to expand, creating growing demands for early detection, accurate diagnosis, differential testing and sustained surveillance.

Macro & Micro-Test provides an integrated Dengue testing portfolio spanning rapid antigen and antibody testing, molecular detection, serotype identification and arbovirus differentiation, helping laboratories and healthcare providers select appropriate testing approaches across different stages of infection and testing environments.

Global Dengue Challengue-A Growing Global Public Health Threat

Dengue is now endemic in 128 countries, with WHO estimating approximately 400 million DENV infections and around 100 million symptomatic cases annually. The disease continues to place pressure on healthcare systems, particularly during outbreaks and periods of increased transmission.

The challenge extends beyond the number of infections:

-Expanding Geographic Distribution: Dengue transmission has expanded beyond traditional endemic areas, increasing the need for flexible diagnostic capacity and strengthened surveillance.

-Similar Clinical Presentations: Early dengue can resemble other febrile and arboviral diseases, including chikungunya and Zika, making clinical differentiation alone unreliable.

-A Narrow Window for Early Detection：During the early stage of infection, viral RNA and NS1 antigen can be detected, while antibody responses develop over time. Selecting the right test at the right time is therefore critical.

-Increasing Need for Laboratory Confirmation: Accurate laboratory testing supports not only patient diagnosis, but also outbreak investigation, epidemiological surveillance and public health response.

The challenge is not simply detecting Dengue — it is knowing what to test, when to test and how to interpret the result.

WHO Guidance: Testing According to the Stage of Infection

Matching the Right Test to the Right Time

WHO’s Laboratory Testing for Dengue Virus: Interim Guidance, April 2025 emphasizes that dengue diagnostic strategies should be adapted according to the stage of illness, local epidemiology, circulating orthoflaviviruses and laboratory capacity. WHO notes that there is no single universal diagnostic algorithm applicable to every setting.

-Acute Phase-Approximately Day 1–7

Preferred direct detection approaches include: DENV RNA by NAAT / RT-PCR,  or NS1 Antigen  by ELISA / Rapid Diagnostic Test.These methods support early detection when viral RNA and NS1 antigen are more likely to be detectable.

-Later Stage - After Day 7

IgM antibody testing becomes increasingly important for identifying recent dengue infection. Additional serological investigation, including paired samples and evidence of seroconversion where appropriate, may be required when initial results are inconclusive.

-When Differential Diagnosis Is Needed

Negative dengue results do not necessarily end the diagnostic investigation. WHO recommends considering other arboviruses and febrile diseases, particularly where Dengue, Zika, Chikungunya or other orthoflaviviruses co-circulate.

Macro & Micro-Test Dengue Testing Portfolio

One Portfolio. Multiple Testing Needs.

Macro & Micro-Test translates this stage-based diagnostic concept into a flexible testing portfolio:

Rapid Screening → Early Detection → Serological Assessment → Precision Molecular Diagnosis → Arbovirus Differentiation → Automated Molecular Testing

Scenario 1 - Rapid Screening & Targeted Surveillance-For Frontline and Decentralized Testing

Application Settings: Fever clinics • Primary healthcare facilities • Community screening • Outbreak-affected areas • Port health and border quarantine stations

-Dengue NS1 Antigen Detection: Supports early detection during the acute phase, with results available in as little as 15 minutes.

-Dengue Virus IgM/IgG Antibody Detection: Provides complementary serological information to support dengue diagnosis and interpretation of infection status together with clinical history and other laboratory findings.

-Dengue NS1 Antigen + IgM/IgG Dual Detection-Combines NS1 antigen and IgM/IgG antibody detection to extend diagnostic coverage across different stages of infection.

NS1 supports early acute-phase detection, while antibody markers provide complementary information as the immune response develops.

High Performance & Reliable Results

• High sensitivity and specificity
• No cross-reactivity with common pathogens
• Built-in control lines for valid test interpretation
• Designed for frontline and decentralized testing

Simple Operation. Rapid Turnaround.

• No instrumentation required
• Results in 15–20 minutes
• Supports serum, plasma and whole blood
• Suitable for on-site and decentralized testing

Room-Temperature Storage. Flexible Deployment.

Store at 4–30°C with a 24-month shelf life, supporting deployment across fever clinics, primary healthcare facilities, border health stations and outbreak-response settings.

Rapid Test Portfolio

Scenario 2 - Precision Diagnosis & Emergency Response -For Clinical and Public Health Laboratories

Application Settings: Hospital clinical laboratories • National and regional CDC laboratories • Mobile laboratories • Outbreak-response laboratories

Comprehensive DENV Detection

The molecular portfolio covers all four DENV serotypes: DENV-1, DENV-2, DENV-3 and DENV-4, supporting molecular diagnosis and serotype-level surveillance.

Arbovirus Differentiation

The multiplex assay simultaneously detects:Dengue Virus + Zika Virus + Chikungunya Virus

This provides a molecular approach for differentiating major arboviruses with overlapping clinical presentations.

Flexible Molecular Workflows

Conventional PCR compatible with mainstream PCR instruments used in conventional molecular laboratories.

Sample-to-Answer with Eudemon™ AIO800

Supports an Sample-to-Answer automated workflow from sample processing to result, providing an additional option for laboratories and outbreak-response settings seeking streamlined molecular testing.

Reliable Molecular Results

• No cross-reactivity with common pathogens
• Robust performance with high sensitivity and specificity
• Built-in internal control for quality assurance
• Supports molecular detection and surveillance workflows

Molecular Detection Portfolio

One Portfolio. Multiple Testing Needs.

Supporting Dengue Diagnosis, Surveillance and Outbreak Response

From rapid screening at the frontline to molecular diagnosis in clinical and public health laboratories, Macro & Micro-Test provides flexible Dengue testing solutions aligned with the evolving needs of dengue diagnosis and surveillance.

Better Testing. Better Decisions. A Healthier World.

Macro & Micro-Test-Precise Diagnosis Shapes a Better Life.